Literature DB >> 9710528

Development of cataplexy in genetically narcoleptic Dobermans.

J Riehl1, S Nishino, R Cederberg, W C Dement, E Mignot.   

Abstract

Forty-two genetically narcoleptic Doberman puppies [20 pure narcoleptic (N) puppies (from four narcoleptic x narcoleptic crosses) and 22 backcross narcoleptic (BN) puppies (from six narcoleptic x heterozygous crosses)] were systematically observed during the developmental period (4-24 weeks) to assess the age at onset and severity of cataplexy, a pathological manifestation of REM sleep atonia seen in narcolepsy. The mean age of onset of cataplexy was 9.69 +/- 1.15 weeks, with a median age of 7 weeks. The severity of cataplexy increased with age and reached a plateau at around 16-24 weeks. The effects of cross type (N vs BN) and sex on the development of cataplexy were analyzed. There was no difference in severity between N and BN puppies (P = 0.51). However, females had more severe cataplexy than males (P = 0.01), and this trend was preserved in five of the six litters that had both male and female puppies. These results suggest that the pathophysiological process in genetic canine narcolepsy emerges during the early developmental period and that it may involve a differential development in males and females. Furthermore, our results revealed that cataplexy onset corresponds to the emergence of adult-like REM sleep and to previously reported neuroanatomical and neurochemical abnormalities in canine narcolepsy. Copyright 1998 Academic Press.

Entities:  

Mesh:

Year:  1998        PMID: 9710528     DOI: 10.1006/exnr.1998.6847

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  10 in total

Review 1.  Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.

Authors:  S Nishino; E Mignot
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

Review 2.  Clinical and neurobiological aspects of narcolepsy.

Authors:  Seiji Nishino
Journal:  Sleep Med       Date:  2007-04-30       Impact factor: 3.492

3.  Developmental divergence of sleep-wake patterns in orexin knockout and wild-type mice.

Authors:  Mark S Blumberg; Cassandra M Coleman; Eric D Johnson; Cynthia Shaw
Journal:  Eur J Neurosci       Date:  2007-01       Impact factor: 3.386

4.  Developmental changes in CSF hypocretin-1 (orexin-A) levels in normal and genetically narcoleptic Doberman pinschers.

Authors:  Joshi John; Ming-Fung Wu; Nigel T Maidment; Hoa A Lam; Lisa N Boehmer; Melanie Patton; Jerome M Siegel
Journal:  J Physiol       Date:  2004-08-12       Impact factor: 5.182

5.  Animal models of narcolepsy.

Authors:  Lichao Chen; Ritchie E Brown; James T McKenna; Robert W McCarley
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-08       Impact factor: 4.388

6.  A brief history of hypocretin/orexin and narcolepsy.

Authors:  J M Siegel; R Moore; T Thannickal; R Nienhuis
Journal:  Neuropsychopharmacology       Date:  2001-11       Impact factor: 7.853

Review 7.  Raising awareness about sleep disorders.

Authors:  Stuti J Jaiswal; Robert L Owens; Atul Malhotra
Journal:  Lung India       Date:  2017 May-Jun

8.  Pituitary Macrotumor Causing Narcolepsy-Cataplexy in a Dachshund.

Authors:  S Schmid; A Hodshon; S Olin; I Pfeiffer; S Hecht
Journal:  J Vet Intern Med       Date:  2017-01-15       Impact factor: 3.333

9.  Reduced expression of TAC1, PENK and SOCS2 in Hcrtr-2 mutated narcoleptic dog brain.

Authors:  Julia Lindberg; Peter Saetre; Seiji Nishino; Emmanuel Mignot; Elena Jazin
Journal:  BMC Neurosci       Date:  2007-05-23       Impact factor: 3.288

10.  Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity.

Authors:  L N Boehmer; M-F Wu; J John; J M Siegel
Journal:  Exp Neurol       Date:  2004-08       Impact factor: 5.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.